Neo-Endusix (Tenoxicam)

Tenoxicam works by inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for the synthesis of prostaglandins. Prostaglandins mediate inflammation, pain, and fever, so their reduction leads to decreased swelling, pain relief, and lower temperature at sites of tissue injury.

The appropriate dose of Neo-Endusix is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety of Tenoxicam in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a qualified healthcare professional.

To place an order, submit an enquiry on the Neo-Endusix product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Tenoxicam is a long‑acting NSAID with a relatively favorable gastrointestinal profile compared with some older agents, but it shares the class‑wide risks of bleeding, renal impairment and cardiovascular events. Compared with ibuprofen or diclofenac, Tenoxicam may require less frequent dosing, yet individual response and tolerability vary.

Neo-Endusix should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, controlled environment helps maintain its stability and potency throughout its shelf life.

Neo-Endusix is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can reduce the likelihood of gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include gastrointestinal bleeding or ulcer perforation, severe skin reactions such as Stevens‑Johnson syndrome, acute renal failure, hepatic dysfunction, and anaphylactic shock. Patients should seek immediate medical attention if they experience symptoms like black stools, severe rash, swelling of the face or throat, or sudden loss of kidney function.

Neo-Endusix should be avoided in individuals with known hypersensitivity to Tenoxicam or other NSAIDs, active gastrointestinal ulceration or bleeding, severe heart failure, uncontrolled hypertension, and in patients with significant renal or hepatic impairment unless specifically directed by a physician.